When: July 16th, 2pm ET
Where: Online – register below
Douglas CDMO will participate in Outsourced Pharma’s Capacity Update Week July 2025, a digital event designed to provide an inside look at the capabilities and capacities of leading CDMOs. This interactive platform allows pharmaceutical and biotech companies to engage with industry experts, ask questions, and assess potential partnerships—all from the convenience of their computer.
As a fully integrated CDMO proudly based in New Zealand, Douglas CDMO offers end-to-end drug development and manufacturing services, specializing in formulating and commercially supplying innovative and generic high-potency small molecule softgels and liquids.
In this session, learn how Douglas CDMO helps partners navigate complex formulation challenges and bring high-quality therapies to market efficiently. Our capabilities extend to producing prescription drugs across key therapeutic areas, including dermatology, oncology, endocrinology and the central nervous system. Quality and service underpin our business, and we are committed to delivering exceptional results to our clients.
In this session, Lora Wallis, Head of Delivery, and Chris Cuthbertson, Program Manager, share insights into Douglas CDMO’s capabilities, flexible approach, and commitment to accelerating pharmaceutical innovation. Register to watch the recording live or view following the webcast.
Lora Wallis, Head of Delivery – Pharma
Other posts you may be interested in...
Articles
Bespoke client solutions: A personalized approach as a privately owned CDMO
Douglas CDMO is making its mark in the pharmaceutical development industry with their flexible and personalized approaches to client needs.
Learn MoreArticles
Smart softgels: driving innovation in pharma
In the dynamic landscape of pharmaceuticals, one innovation has consistently pushed the boundaries of drug delivery: the softgel capsule.
Learn MoreCase Studies
Seizing market share pre-patent expiry: Navigating a paragraph IV ANDA submission
Douglas CDMO partnered with a US pharmaceutical firm to develop a cutting-edge generic isotretinoin softgel, overcoming regulatory and technical complexities, launching with remarkable success.
Learn More